Nedocromil, a mucosal and connective tissue mast cell stabilizer, inhibits exercise-induced asthma.
Nedocromil, the disodium salt of a pyranoquinoline dicarboxylic acid, has a similar profile of activity to disodium cromoglycate (DSCG) but appears to be more active in stabilizing mucosal-type mast cells. In a double-blind placebo-controlled trial nedocromil (2 mg) was given by inhalation to eight asthmatic patients prior to a treadmill exercise task. There was a significant reduction in the fall in FEV1 (P less than 0.01) and FVC (P less than 0.05) after nedocromil when compared to placebo. This study indicates that nedocromil might be an effective anti-asthma agent and in addition may help define the role of the mucosal mast cell.
D000293:Adolescent; D000328:Adult; D001249:Asthma / Q000517:prevention & control*; D001250:Asthma, Exercise-Induced / Q000503:physiopathology / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005541:Forced Expiratory Volume; D006801:Humans; D008168:Lung / Q000503:physiopathology; D008297:Male; D008407:Mast Cells / Q000187:drug effects*; D008875:Middle Aged; D017835:Nedocromil; D011804:Quinolines / Q000627:therapeutic use*; D014797:Vital Capacity
D011804:Quinolines; D017835:Nedocromil